Oramed Net Income Per Share vs Pocfratio Analysis
ORMP Stock | USD 2.51 0.01 0.40% |
Oramed Pharmaceuticals financial indicator trend analysis is much more than just breaking down Oramed Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oramed Pharmaceuticals is a good investment. Please check the relationship between Oramed Pharmaceuticals Net Income Per Share and its Pocfratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.
Net Income Per Share vs Pocfratio
Net Income Per Share vs Pocfratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oramed Pharmaceuticals Net Income Per Share account and Pocfratio. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Oramed Pharmaceuticals' Net Income Per Share and Pocfratio is -0.38. Overlapping area represents the amount of variation of Net Income Per Share that can explain the historical movement of Pocfratio in the same time period over historical financial statements of Oramed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Oramed Pharmaceuticals' Net Income Per Share and Pocfratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income Per Share of Oramed Pharmaceuticals are associated (or correlated) with its Pocfratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pocfratio has no effect on the direction of Net Income Per Share i.e., Oramed Pharmaceuticals' Net Income Per Share and Pocfratio go up and down completely randomly.
Correlation Coefficient | -0.38 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Net Income Per Share
Pocfratio
Most indicators from Oramed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oramed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.As of 12/11/2024, Selling General Administrative is likely to grow to about 8.8 M, while Tax Provision is likely to drop 0.00.
2020 | 2023 | 2024 (projected) | Gross Profit | 2.6M | 1.3M | 1.9M | Total Revenue | 2.7M | 1.3M | 2.0M |
Oramed Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Oramed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oramed Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Current Liab | (69K) | 601K | (1.4M) | (191K) | 1.4M | 1.5M | |
Total Current Liabilities | 5.3M | 4.5M | 6.7M | 5.7M | 53.2M | 55.9M | |
Total Stockholder Equity | 19.4M | 32.9M | 115.8M | 151.8M | 163.8M | 172.0M | |
Retained Earnings | (81.1M) | (92.6M) | (114.9M) | (163.1M) | (157.6M) | (149.7M) | |
Common Stock Shares Outstanding | 17.5M | 20.5M | 28.5M | 39.0M | 40.6M | 42.6M | |
Other Stockholder Equity | 100.3M | 125.2M | 230.2M | 314.4M | 320.9M | 336.9M | |
Total Liab | 15.3M | 11.8M | 11.5M | 10.5M | 57.7M | 60.5M | |
Common Stock | 208K | 284K | 424K | 476K | 485K | 509.3K | |
Total Assets | 34.7M | 44.6M | 128.0M | 161.6M | 220.6M | 231.6M | |
Net Debt | (3.3M) | (19.2M) | (76.7M) | (39.6M) | 42.6M | 44.7M | |
Accounts Payable | 1.3M | 594K | 2.6M | 2.2M | 551K | 822.2K | |
Cash | 3.3M | 19.3M | 77.2M | 40.5M | 9.1M | 10.6M | |
Cash And Short Term Investments | 32.3M | 39.9M | 94.1M | 155.7M | 162.0M | 170.1M | |
Liabilities And Stockholders Equity | 34.7M | 44.6M | 128.0M | 161.6M | 220.6M | 231.6M | |
Non Current Liabilities Total | 10.0M | 7.2M | 4.8M | 4.7M | 4.4M | 4.2M | |
Other Current Assets | 1.0M | 611K | 1.2M | 1.4M | 537K | 536.1K | |
Total Current Assets | 33.3M | 40.5M | 95.3M | 157.1M | 162.6M | 170.7M | |
Property Plant And Equipment Net | 24K | 174K | 932K | 1.8M | 1.6M | 1.6M | |
Non Current Assets Total | 1.3M | 4.1M | 32.7M | 4.5M | 58.0M | 60.9M | |
Short Term Investments | 29.0M | 20.6M | 16.9M | 115.3M | 153.0M | 160.6M |
Pair Trading with Oramed Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Oramed Stock
The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.
The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.